ABIOMED, Inc.  

(Public, NASDAQ:ABMD)   Watch this stock  
Find more results for abmd
117.97
+2.94 (2.56%)
After Hours: 117.98 +0.01 (0.01%)
Jul 29, 4:44PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 115.24 - 119.93
52 week 67.81 - 119.93
Open 115.24
Vol / Avg. 880,073.00/760,962.00
Mkt cap 5.03B
P/E 138.79
Div/yield     -
EPS 0.85
Shares 43.01M
Beta 1.09
Inst. own 96%
Oct 27, 2016
Q2 2017 Abiomed Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Aug 11, 2016
Abiomed Inc Annual Shareholders Meeting (Estimated) - 8:00AM EDT - Add to calendar
Aug 10, 2016
Abiomed Inc Annual Shareholders Meeting - 8:00AM EDT - Add to calendar
Jul 28, 2016
Q1 2017 Abiomed Inc Earnings Release
Jul 28, 2016
Q1 2017 Abiomed Inc Earnings Call - Webcast
Jun 14, 2016
Abiomed Inc at William Blair Growth Stock Conference
Jun 9, 2016
Abiomed Inc at Jefferies Healthcare Conference
May 3, 2016
Q4 2016 Abiomed Inc Earnings Release
May 3, 2016
Q4 2016 Abiomed Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2016
Net profit margin 11.71% 11.58%
Operating margin 21.09% 19.76%
EBITD margin - 20.76%
Return on average assets 10.82% 10.01%
Return on average equity 12.35% 11.55%
Employees 747 -
CDP Score - -

Address

22 CHERRY HILL DR
DANVERS, MA 01923-2575
United States - Map
+1-978-7775410 (Phone)
+1-978-7778411 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Officers and directors

Michael R. Minogue Chairman of the Board, President, Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael Tomsicek Chief Financial Officer, Vice President, Treasurer
Age: 49
Bio & Compensation  - Reuters
David M. Weber Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
William J. Bolt Senior Vice President - Global Product Operations
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Andrew J. Greenfield Vice President, General Manager - Global Marketing
Age: 42
Bio & Compensation  - Reuters
Michael G. Howley Vice President, General Manager - Global Sales and Marketing
Age: 51
Bio & Compensation  - Reuters
Ingrid Goldberg Director - Investor Relations
Bio & Compensation  - Reuters
Dorothy E. Puhy Lead Independent Director
Age: 64
Bio & Compensation  - Reuters
Jeannine M. Rivet Director
Age: 62
Bio & Compensation  - Reuters
Christopher D. Van Gorder Director
Bio & Compensation  - Reuters